Precision Biologics, Inc. to present recent data on the development of new monoclonal antibody (mAb) PB-223 at SITC 2024

Precision Biologics, Inc. to present recent data on the development of new monoclonal antibody (mAb) PB-223 at SITC 2024

Precision Biologics, Inc. will present novel data about affinity maturation and characterization of a novel Core 2 O-glycan epitope-targeting anti-human carcinoma mAb, PB-223, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting, George R. Brown Convention Center, Houston, TX, at: SITC Immune Engineering Workshop, November 7th, 3.10 p.m-5 p.m. CST, Level 3 – Grand Ballroom AB, Houston, TX; and SITC Poster Session Immuno-Engineering, abstract number 1101, November 8th, 12:15–1:45 p.m. CST and 5:30-7 p.m. CST, Level 1-Exhibit Halls A B, Houston, Texas, USA.

Share this post